Free tool
FAERS Monitor: Naftin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019599 or its brand name (Naftin, Naftifine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
334
Serious
161
48% of reports
Hospitalization
68
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus33
- blister27
- skin exfoliation26
- hypersensitivity25
- chronic kidney disease24
- drug ineffective24
- rash23
- erythema21
- off label use20
- diarrhoea18
- pain18
- renal failure18
- acute kidney injury15
- burning sensation13
- headache12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 9 |
| 2012 | 14 |
| 2013 | 12 |
| 2014 | 14 |
| 2015 | 34 |
| 2016 | 46 |
| 2017 | 24 |
| 2018 | 32 |
| 2019 | 33 |
| 2020 | 28 |
| 2021 | 23 |
| 2022 | 18 |
| 2023 | 13 |
| 2024 | 9 |
| 2025 | 10 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blisterSignal | 27 | 30.3 | 21.1 | 737 |
| chronic kidney diseaseSignal | 24 | 19.9 | 13.5 | 413 |
| skin exfoliationSignal | 26 | 19.4 | 13.4 | 437 |
| burning sensationSignal | 13 | 11.7 | 6.9 | 117 |
| renal failureSignal | 18 | 8.5 | 5.4 | 113 |
| hypersensitivitySignal | 25 | 8.5 | 5.8 | 159 |
| erythemaSignal | 21 | 6.4 | 4.3 | 92 |
| acute kidney injurySignal | 15 | 6.2 | 3.8 | 60 |
| pruritusSignal | 33 | 5.4 | 3.9 | 116 |
| rashSignal | 23 | 3.3 | 2.2 | 36 |
| pain | 18 | 1.8 | 1.2 | 6 |
| diarrhoea | 18 | 1.8 | 1.1 | 5 |
| off label use | 20 | 1.4 | 0.9 | 2 |
| headache | 12 | 1.2 | 0.7 | 0 |
| drug ineffective | 24 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.